Feature

Decline in non-Hodgkin lymphoma deaths to continue in 2018


 

Mortality from non-Hodgkin lymphoma is expected to be about 6.1 per 100,000 population in 2018, with the highest rate in Maine and West Virginia and the lowest in Utah.

Approximately 19,910 deaths from non-Hodgkin lymphoma (NHL) are predicted for the year in the United States by the American Cancer Society (ACS) in its Cancer Facts & Figures 2018, based on analysis of 2001-2015 data from the National Center for Health Statistics. That figure is down from the 20,140 predicted for 2017, as the trend in the death rate since 2006 has been a decline of about 2% per year.

Estimated non-Hodgkin lymphoma death rates for 201
The expected number of deaths for 2018, coupled with a current population estimate of nearly 326 million, works out to an expected death rate of 6.1 per 100,000 population. The Census Bureau estimates for the state populations and the deaths projected by the ACS produce expected death rates of 8.2 per 100,000 for Maine and West Virginia and 4.2 for Utah.

Nationally, death rates for NHL were 7.4 per 100,000 for males and 4.5 for females for 2011-2015, and incidence rates were 22.9 per 100,000 for males and 15.8 for females for 2010-2014, the ACS reported.

Over time, the relative survival rate for NHL has gone from 47% in 1975-1977 to 51% in 1987-1989 to 73% in 2007-2013, although there is some disparity between whites, whose respective rates are 47%, 51%, and 74%, and blacks, who have rates of 49%, 46%, and 67%, respectively, the ACS said.

Recommended Reading

Lupus and diffuse large B-cell lymphoma share genetic risk
MDedge Internal Medicine
Pregnancy did not increase Hodgkin lymphoma relapse rate
MDedge Internal Medicine
HIV-related lymphoma rate remains sky-high despite ART
MDedge Internal Medicine
Cancer trends shifting in HIV-positive patients
MDedge Internal Medicine
Hepatitis infection raises non-Hodgkin lymphoma risk in HIV patients
MDedge Internal Medicine
Hodgkin lymphoma survival has nearly tripled since the 1950s
MDedge Internal Medicine
Long view shows doubling of survival in non-Hodgkin lymphoma
MDedge Internal Medicine
Neuropathic pain puts cancer survivors out of work
MDedge Internal Medicine
Phase III trial: VZV protects auto-HCT patients
MDedge Internal Medicine
Connective tissue diseases reported in patients receiving immune checkpoint inhibitors
MDedge Internal Medicine